CARLOS VELA: Open Payments
NPI 1124219639 · EDINBURG, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,070 in 50 payments from 13 companies in 2025. Trend: 2023 $2,081 · 2024 $2,590 · 2025 $2,070
Food & beverage: $2,070
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 14 | $415 |
| Dexcom, Inc. | 4 | $398 |
| Abbott Laboratories | 5 | $241 |
| Novo Nordisk Inc | 11 | $238 |
| Optinose US, Inc. | 4 | $180 |
| Lilly USA, LLC | 4 | $140 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $124 |
| Vifor Pharma, Inc. | 1 | $120 |
| Inspire Medical Systems, Inc. | 1 | $119 |
| AstraZeneca Pharmaceuticals LP | 2 | $37 |
Products named: REPATHA, Dexcom G6 Transmitter, JOT DX, Xhance, Ozempic, MOUNJARO, XIFAXAN, Veltassa.
Industry payments across TX — which companies pay providers there.
